The insider sales are too small to be informative. Focus on the $400M shelf registration and going-concern risk: KPTI must raise capital by late Q3 2026, which will likely cause severe dilution. Monitor for any ATM debuts or equity offering announcements.
KPTI drugs
KPTI drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 18 $7.14entry
- T+1 · 6mo ago +4.62%α +5.27% · $7.47
- T+5 · 6mo ago +25.63%α +24.01% · $8.97
- T+20 · 5mo ago +27.45%α +25.87% · $9.10
- T+60 · 3mo ago −71.57%α −76.42% · $2.03
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Six KPTI insiders, including the CEO and other C-suite executives, sold a total of $35K in shares on May 14, 2026, the same day as the Q1 earnings release. The sales are minimal in size (0.019% of market cap) and likely routine post-earnings transactions. Three directors received non-cash stock grants on May 21. The sales do not signal bearish sentiment given their trivial value, but the company faces significant going-concern risk and potential dilution from a $400M shelf registration.
Key Financial Metrics
Key Facts
- Six C-suite insiders sold a total of $35K in shares on May 14, 2026, all at $9.50/share.
- Three directors received grants of 15,508 shares each on May 21, 2026, at $0 (non-cash).
- Total insider sales represent 0.019% of KPTI's $185M market cap, well below materiality threshold.
- Q1 2026 revenue was $35.1M (up 17% YoY), net loss $22.4M, beat consensus EPS of -$1.44 by 29%.
- Phase 3 SENTRY myelofibrosis trial missed second co-primary endpoint; $400M shelf registration filed.
- Cash runway extends only into late Q3 2026, creating acute financing risk.
Financial Impact
Insider sales of $35K are immaterial; the shelf registration of $400M (216% of market cap) is the key risk.
Risk Factors
- Potential massive dilution from the $400M shelf registration relative to $185M market cap.
- Going concern with cash runway only to late Q3 2026.
- Phase 3 SENTRY trial failure limits pipeline upside.
- Insider sales, while small, occur amid high uncertainty.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-KPTI-1779826471396 |
Track record
30 reports on KPTI
5 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +97.24% at T+60 after the Aug 13, 2026 report. 13 of 14 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $0.0102 Now $0.0290 +184.31% settles Feb 12
- Nov 13, 20263d ago NT 10-Q Bearish 7/10 Entry $0.0102 Now $0.0290 −184.31% settles Feb 12
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $0.0260 Now $0.0290 +11.54% settles Feb 10
- Nov 9, 20267d ago SC 13G/A Neutral 2/10 Entry $0.0400 Now $0.0290 −27.50% settles Feb 5
- Nov 5, 202611d ago 8-K Bearish 8/10 Entry $0.0601 Now $0.0290 +51.75% settles Feb 3
- Nov 2, 202614d ago 8-K Bearish 10/10 Entry $0.0883 Now $0.0290 +67.16% settles Feb 1
- Nov 2, 202614d ago 8-K Bearish 7/10 Entry $0.1120 Now $0.0290 +74.11% settles Jan 29
- Oct 28, 202619d ago SC 13G/A Bearish 5/10 Entry $0.8798 Now $0.0290 +96.70% settles Jan 27
- Oct 22, 202625d ago 8-K Bearish 6/10 Entry $0.5175 Now $0.0290 +94.40% settles Jan 21
- Oct 14, 20264w ago 8-K Neutral 3/10 Entry $0.3150 Now $0.0290 −90.79% settles Jan 11
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers